Xpovio (Selinexor) Patent Expiration, LOE Window & CMS Spending

Xpovio (Selinexor) by Karyopharm Therapeutics: FDA Orange Book core substance LOE 2035-08-14, 0 AB generics, $105.2M 2024 CMS Part D & Medicaid spend, and 35 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorKaryopharm Therapeutics
FDA Application & PathwayN212306 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2035-08-14
Last Listed Patent or Exclusivity Date2035-08-14
Orange Book Patents (*PED Extensions)11 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$105.2M
2024 Medicare Part D Spend$98.2M
2024 Medicaid Spend$7.0M
Reported Wholesale Price Change (CA SB 17)35 WAC filings (max 32.9% 2-yr change)